{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:45:38Z","timestamp":1785321938442,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Non-Hodgkin\u2019s Lymphoma (NHL) is the most common subtype of lymphoma. The incidence of venous thromboembolism (VTE) in aggressive NHL was estimated recently to be 11%. Several risk assessment scores and factors are available to help identify cancer patients at risk for developing VTE. Patients with a pathologically confirmed diagnosis of NHL were identified at the Oncology Center of Mansoura University. The study included 777 patients: 719 with DLBCL-NOS, 26 with Anaplastic-B-cell, and 32 with T-cell-rich-NHL. Data were retrospectively collected from electronic medical records, including clinical, radiological, and laboratory information related to VTE and NHL. The median age at NHL diagnosis was 53 years, (range: 18\u201398). There was a male predominance, 51.4% of the cases. At initial lymphoma diagnosis, VTE was identified in 46 (5.9%) patients, and 61 (7.9%) patients experienced VTE while undergoing chemotherapy. According to logistic regression analysis, a PS (performance status)\u2009\u2265\u20092, bulky lesions, and mediastinal masses were significant predictors of VTE at presentation, with <jats:italic>P<\/jats:italic>-values of 0.022, 0.002, and &lt;\u20090.001, respectively. Meanwhile, NHL patients who developed VTE during chemotherapy had significantly poorer PS, higher absolute neutrophilic counts (ANC), neutrophil\/lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and lactate dehydrogenase (LDH) levels than lymphoma patients without VTE, with <jats:italic>P<\/jats:italic>-values of 0.003, \u00a00.034, 0.049, 0.01\u00a0and 0.007, respectively, as determined by multivariate analysis. The ROC curve identified the cut-off values of 4.875\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L for ANC, 2.985 for NLR, 144.85 for PLR, and 417.5 U\/L for LDH as potential markers for predicting VTE in NHL patients. Patients with a PS\u2009\u2265\u20092 and values exceeding these cut-offs for ANC, NLR, and PLR experienced significantly higher incidences of VTE than other groups, with <jats:italic>P-<\/jats:italic>values of 0.003, &lt;\u20090.001, &lt;\u20090.001, and &lt;\u20090.001, respectively. At the end of the follow-up, the overall survival was significantly shortened by VTE occurring during chemotherapy, hypoalbuminemia, \u00a0intermediate-high and high international prognostic index (IPI) scores (intermediate-high and high), responses other than CR and relapse, all with <jats:italic>P-<\/jats:italic>values\u2009&lt;\u20090.05. ECOG PS and Inflammatory markers such as NLR, PLR, and neutrophilic count could serve as predictors of the development of thrombotic events in patients with NHL-DLBCL. Additionally, the occurrence of VTE during chemotherapy is an independent poor prognostic marker for overall survival (OS).<\/jats:p>","DOI":"10.1007\/s00277-024-05904-8","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T04:03:51Z","timestamp":1723003431000},"page":"4271-4283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the incidence, predictors, risk assessment scores and outcomes of thromboembolism in a cohort of Egyptian NHL patients - Real World Experience"],"prefix":"10.1007","volume":"103","author":[{"given":"Shaimaa","family":"El-Ashwah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Elashwah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omnia","family":"Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadeer Elsaeed","family":"AboElfarh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramadan Ayman","family":"Selim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reham Osama","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Shaaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"issue":"6","key":"5904_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 68(6):394\u2013424","journal-title":"Cancer J Clin"},{"issue":"1","key":"5904_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. Ca Cancer J Clin 73(1):17\u201348","journal-title":"Ca Cancer J Clin"},{"key":"5904_CR3","doi-asserted-by":"crossref","unstructured":"Ibrahim AH, Shash E (2022) General Oncology Care in Egypt. Cancer in the Arab World: Springer Singapore Singapore; pp. 41\u201361","DOI":"10.1007\/978-981-16-7945-2_4"},{"issue":"9","key":"5904_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/d41573-019-00051-6","volume":"18","author":"K Chaudhari","year":"2019","unstructured":"Chaudhari K, Rizvi S, Syed BA (2019) Non-hodgkin lymphoma therapy landscape. Nat Rev Drug Discov 18(9):663\u2013664","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"5904_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jjcc.2018.02.011","volume":"72","author":"M Mukai","year":"2018","unstructured":"Mukai M, Oka T (2018) Mechanism and management of cancer-associated thrombosis. J Cardiol 72(2):89\u201393","journal-title":"J Cardiol"},{"issue":"1","key":"5904_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.thromres.2012.10.008","volume":"131","author":"G Gussoni","year":"2013","unstructured":"Gussoni G, Foglia E, Frasson S, Casartelli L, Campanini M, Bonfanti M et al (2013) Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients. Thromb Res 131(1):17\u201323","journal-title":"Thromb Res"},{"issue":"17","key":"5904_CR7","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1056\/NEJM199804233381701","volume":"338","author":"HT S\u00f8rensen","year":"1998","unstructured":"S\u00f8rensen HT, Mellemkj\u00e6r L, Steffensen FH, Olsen JH, Nielsen GL (1998) The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338(17):1169\u20131173","journal-title":"N Engl J Med"},{"issue":"6","key":"5904_CR8","doi-asserted-by":"publisher","first-page":"e2317945","DOI":"10.1001\/jamanetworkopen.2023.17945","volume":"6","author":"KL Martens","year":"2023","unstructured":"Martens KL, Li A, La J, May SB, Swinnerton KN, Tosi H et al (2023) Epidemiology of Cancer-Associated venous thromboembolism in patients with solid and hematologic neoplasms in the Veterans Affairs Health Care System. JAMA Netw Open 6(6):e2317945\u2013e","journal-title":"JAMA Netw Open"},{"key":"5904_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.thromres.2016.05.008","volume":"143","author":"K Sanfilippo","year":"2016","unstructured":"Sanfilippo K, Wang T, Gage B, Luo S, Riedell P, Carson K (2016) Incidence of venous thromboembolism in patients with non-hodgkin lymphoma. Thromb Res 143:86\u201390","journal-title":"Thromb Res"},{"issue":"8","key":"5904_CR10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/ajh.25837","volume":"95","author":"G Dharmavaram","year":"2020","unstructured":"Dharmavaram G, Cao S, Sundaram S, Ayyappan S, Boughan K, Gallogly M et al (2020) Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma-specific venous thrombosis prediction models. Am J Hematol 95(8):918\u2013926","journal-title":"Am J Hematol"},{"key":"5904_CR11","doi-asserted-by":"crossref","unstructured":"Elshoury A, Schaefer JK, Lim MY, Skalla DP, Streiff MB (2022) Update on guidelines for the prevention of cancer-associated thrombosis. J Natl Compr Canc Netw. ;20(13)","DOI":"10.6004\/jnccn.2021.7108"},{"issue":"5","key":"5904_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/cc12892","volume":"17","author":"A Koch","year":"2013","unstructured":"Koch A, Meesters MI, Scheller B, Boer C, Zacharowski K (2013) Systemic endotoxin activity correlates with clot formation: an observational study in patients with early systemic inflammation and sepsis. Crit Care 17(5):1\u20138","journal-title":"Crit Care"},{"issue":"10","key":"5904_CR13","first-page":"4902","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood J Am Soc Hematol 111(10):4902\u20134907","journal-title":"Blood J Am Soc Hematol"},{"issue":"4","key":"5904_CR14","doi-asserted-by":"publisher","first-page":"pky082","DOI":"10.1093\/jncics\/pky082","volume":"2","author":"SB Makgoeng","year":"2018","unstructured":"Makgoeng SB, Bolanos RS, Jeon CY, Weiss RE, Arah OA, Breen EC et al (2018) Markers of immune activation and inflammation, and non-hodgkin lymphoma: a meta-analysis of prospective studies. JNCI cancer Spectr 2(4):pky082","journal-title":"JNCI cancer Spectr"},{"issue":"1","key":"5904_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12959-022-00381-3","volume":"20","author":"V Otasevic","year":"2022","unstructured":"Otasevic V, Mihaljevic B, Milic N, Stanisavljevic D, Vukovic V, Tomic K et al (2022) Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients. Thromb J 20(1):1\u201310","journal-title":"Thromb J"},{"issue":"4","key":"5904_CR16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/hon.2321","volume":"35","author":"J Rupa-Matysek","year":"2017","unstructured":"Rupa-Matysek J, Gil L, Kroll\u2010Balcerzak R, Bara\u0144ska M, Komarnicki M (2017) Mean platelet volume as a predictive marker for venous thromboembolism and mortality in patients treated for diffuse large B\u2010cell lymphoma. Hematol Oncol 35(4):456\u2013464","journal-title":"Hematol Oncol"},{"issue":"30","key":"5904_CR17","doi-asserted-by":"publisher","first-page":"21190","DOI":"10.18632\/oncotarget.25002","volume":"9","author":"J Rupa-Matysek","year":"2018","unstructured":"Rupa-Matysek J, Gil L, Bara\u0144ska M, Dytfeld D, Komarnicki M (2018) Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma. Oncotarget 9(30):21190","journal-title":"Oncotarget"},{"issue":"1","key":"5904_CR18","doi-asserted-by":"publisher","first-page":"e23010","DOI":"10.1002\/jcla.23010","volume":"34","author":"R Farah","year":"2020","unstructured":"Farah R, Nseir W, Kagansky D, Khamisy-farah R (2020) The role of neutrophil\u2010lymphocyte ratio, and mean platelet volume in detecting patients with acute venous thromboembolism. J Clin Lab Anal 34(1):e23010","journal-title":"J Clin Lab Anal"},{"issue":"5","key":"5904_CR19","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3390\/cancers12051291","volume":"12","author":"S Hohaus","year":"2020","unstructured":"Hohaus S, Bartolomei F, Cuccaro A, Maiolo E, Alma E, D\u2019Al\u00f2 F et al (2020) Venous thromboembolism in lymphoma: risk stratification and antithrombotic prophylaxis. Cancers 12(5):1291","journal-title":"Cancers"},{"issue":"10","key":"5904_CR20","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/ajh.24466","volume":"91","author":"D Antic","year":"2016","unstructured":"Antic D, Milic N, Nikolovski S, Todorovic M, Bila J, Djurdjevic P et al (2016) Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. Am J Hematol 91(10):1014\u20131019","journal-title":"Am J Hematol"},{"issue":"41","key":"5904_CR21","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1055\/s-0033-1349608","volume":"138","author":"U Pelzer","year":"2013","unstructured":"Pelzer U, Sinn M, Stieler J, Riess H (2013) Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy? Dtsch Med Wochenschr 138(41):2084\u20132088","journal-title":"Dtsch Med Wochenschr"},{"issue":"5","key":"5904_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol"},{"issue":"27","key":"5904_CR23","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059","journal-title":"J Clin Oncol"},{"issue":"26","key":"5904_CR24","first-page":"5322","volume":"115","author":"V Caruso","year":"2010","unstructured":"Caruso V, Di Castelnuovo A, Meschengieser S, Lazzari MA, De Gaetano G, Storti S et al (2010) Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood J Am Soc Hematol 115(26):5322\u20135328","journal-title":"Blood J Am Soc Hematol"},{"issue":"6","key":"5904_CR25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.thromres.2010.08.017","volume":"126","author":"D Lekovic","year":"2010","unstructured":"Lekovic D, Miljic P, Mihaljevic B (2010) Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma. Thromb Res 126(6):477\u2013480","journal-title":"Thromb Res"},{"issue":"1","key":"5904_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.thromres.2011.09.022","volume":"130","author":"K Yokoyama","year":"2012","unstructured":"Yokoyama K, Murata M, Ikeda Y, Okamoto S (2012) Incidence and risk factors for developing venous thromboembolism in Japanese with diffuse large b-cell lymphoma. Thromb Res 130(1):7\u201311","journal-title":"Thromb Res"},{"key":"5904_CR27","unstructured":"Gerotziafas GT (2019) La maladie thromboembolique veineuse chez les patients atteints d\u2019une h\u00e9mopathie maligne \u00c9tat des lieux sur l\u2019ampleur du probl\u00e8me. H\u00e9matologie. ;25(1)"},{"key":"5904_CR28","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/S0049-3848(14)50004-7","volume":"133","author":"A Mahajan","year":"2014","unstructured":"Mahajan A, Wun T, Chew H, White RH (2014) Lymphoma and venous thromboembolism: influence on mortality. Thromb Res 133:S23\u2013S8","journal-title":"Thromb Res"},{"key":"5904_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.blre.2018.06.002","volume":"33","author":"N Kekre","year":"2019","unstructured":"Kekre N, Connors JM (2019) Venous thromboembolism incidence in hematologic malignancies. Blood Rev 33:24\u201332","journal-title":"Blood Rev"},{"issue":"7","key":"5904_CR30","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/j.1572-0241.2006.00588.x","volume":"101","author":"PG Northup","year":"2006","unstructured":"Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH et al (2006) Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Official J Am Coll Gastroenterology| ACG 101(7):1524\u20131528","journal-title":"Official J Am Coll Gastroenterology| ACG"},{"issue":"01","key":"5904_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1160\/TH16-06-0450","volume":"26","author":"P Ambrosino","year":"2017","unstructured":"Ambrosino P, Tarantino L, Di Minno G, Paternoster M, Graziano V, Petitto M et al (2017) The risk of venous thromboembolism in patients with cirrhosis. Thromb Haemost 26(01):139\u2013148","journal-title":"Thromb Haemost"},{"key":"5904_CR32","doi-asserted-by":"publisher","first-page":"901887","DOI":"10.3389\/fphar.2022.901887","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Lei H, Wang W, Zhu J, Zeng C, Lu Z et al (2022) Characteristics and predictors of venous thromboembolism among Lymphoma patients undergoing chemotherapy: a Cohort Study in China. Front Pharmacol 13:901887","journal-title":"Front Pharmacol"},{"key":"5904_CR33","doi-asserted-by":"crossref","unstructured":"Taalab MM, Shaaban YE (2023) Prognostic impact of pretreatment serum lactate dehydrogenase levels in adult patients with Acute myeloid leukemia: single Center experience. Benha Med J","DOI":"10.21608\/bmfj.2023.195235.1771"},{"key":"5904_CR34","doi-asserted-by":"crossref","unstructured":"Hohaus S, Massini G, Giachelia M, Vannata B, Bozzoli V, Cuccaro A et al (2010) Anemia in Hodgkin\u2019s lymphoma: the role of interleukin-6 and hepcidin","DOI":"10.1200\/JCO.2009.27.6873"},{"key":"5904_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.trsl.2020.06.012","volume":"225","author":"AS Kim","year":"2020","unstructured":"Kim AS, Khorana AA, McCrae KR (2020) Mechanisms and biomarkers of cancer-associated thrombosis. Translational Res 225:33\u201353","journal-title":"Translational Res"},{"key":"5904_CR36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","volume":"7","author":"M Verso","year":"2012","unstructured":"Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 7:291\u2013292","journal-title":"Intern Emerg Med"},{"key":"5904_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11239-019-01845-6","volume":"48","author":"M Di Nisio","year":"2019","unstructured":"Di Nisio M, van Es N, Rotunno L, Anzoletti N, Falcone L, De Tursi M et al (2019) Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. J Thromb Thrombolysis 48:125\u2013133","journal-title":"J Thromb Thrombolysis"},{"key":"5904_CR38","doi-asserted-by":"crossref","unstructured":"El-Sayed HA, Othman M, Azzam H, Bucciol R, Ebrahim MA, El-Agdar M et al (2023) Assessing the risk of venous thromboembolism in patients with haematological cancers using three prediction models. J Cancer Res Clin Oncol","DOI":"10.22541\/au.168681068.89928298\/v1"},{"issue":"08","key":"5904_CR39","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1160\/TH16-11-0895","volume":"117","author":"RM Santi","year":"2017","unstructured":"Santi RM, Ceccarelli M, Bernocco E, Monagheddu C, Evangelista A, Valeri F et al (2017) Khorana score and histotype predicts incidence of early venous thromboembolism in non-hodgkin lymphomas. Thromb Haemost 117(08):1615\u20131621","journal-title":"Thromb Haemost"},{"key":"5904_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-017-1065-4","volume":"35","author":"J Rupa-Matysek","year":"2018","unstructured":"Rupa-Matysek J, Gil L, Ka\u017amierczak M, Bara\u0144ska M, Komarnicki M (2018) Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana risk score. Med Oncol 35:1\u20138","journal-title":"Med Oncol"},{"issue":"8","key":"5904_CR41","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/annonc\/mdz168","volume":"30","author":"S Borchmann","year":"2019","unstructured":"Borchmann S, M\u00fcller H, Hude I, Fuchs M, Borchmann P, Engert A (2019) Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials. Ann Oncol 30(8):1329\u20131334","journal-title":"Ann Oncol"},{"key":"5904_CR42","doi-asserted-by":"publisher","first-page":"107602962110459","DOI":"10.1177\/10760296211045908","volume":"27","author":"H Abdel-Razeq","year":"2021","unstructured":"Abdel-Razeq H, Ma\u2019koseh M, Mansour A, Bater R, Amarin R, Abufara A et al (2021) The application of the ThroLy risk assessment model to predict venous thromboembolism in patients with diffuse large B-cell lymphoma. Clin Appl Thromb Hemost 27:10760296211045908","journal-title":"Clin Appl Thromb Hemost"},{"issue":"9","key":"5904_CR43","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","volume":"102","author":"N van Es","year":"2017","unstructured":"van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten H-M, Mah\u00e9 I et al (2017) Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica 102(9):1494","journal-title":"Haematologica"},{"issue":"7","key":"5904_CR44","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1002\/cam4.1540","volume":"7","author":"J Rupa-Matysek","year":"2018","unstructured":"Rupa-Matysek J, Brze\u017aniakiewicz\u2010Janus K, Gil L, Krasi\u0144ski Z, Komarnicki M (2018) Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice. Cancer Med 7(7):2868\u20132875","journal-title":"Cancer Med"},{"issue":"6","key":"5904_CR45","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s00277-018-3276-y","volume":"97","author":"A Romano","year":"2018","unstructured":"Romano A, Parrinello NL, Vetro C, Chiarenza A, Cerchione C, Ippolito M et al (2018) Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. Ann Hematol 97(6):1009\u20131018","journal-title":"Ann Hematol"},{"issue":"5","key":"5904_CR46","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1177\/1076029617733039","volume":"24","author":"A Artoni","year":"2018","unstructured":"Artoni A, Abbattista M, Bucciarelli P, Gianniello F, Scalambrino E, Pappalardo E et al (2018) Platelet to lymphocyte ratio and neutrophil to lymphocyte ratio as risk factors for venous thrombosis. Clin Appl Thromb Hemost 24(5):808\u2013814","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"5904_CR47","first-page":"2610","volume":"15","author":"Y Li","year":"2023","unstructured":"Li Y, Zhu Y, Duan X (2023) Prognostic value of multiple immune inflammatory markers in diffuse large B-cell lymphoma. Am J Translational Res 15(4):2610","journal-title":"Am J Translational Res"},{"key":"5904_CR48","doi-asserted-by":"publisher","first-page":"S252","DOI":"10.1016\/j.clml.2019.07.159","volume":"19","author":"A Mohsen","year":"2019","unstructured":"Mohsen A, Taalab MM, Abousamra NK, Mabed M (2019) Prognostic significance of Absolute lymphocyte to Absolute Monocyte count ratio in Egyptian patients with relapsed diffuse large B-Cell lymphoma. Clin Lymphoma Myeloma Leuk 19:S252","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5904_CR49","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.thromres.2018.01.037","volume":"163","author":"BT Samuelson Bannow","year":"2018","unstructured":"Samuelson Bannow BT, Konkle BA (2018) Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: a review. Thromb Res 163:138\u2013145","journal-title":"Thromb Res"},{"key":"5904_CR50","doi-asserted-by":"crossref","unstructured":"Akdeniz A, Mehtap \u00d6, Karaku\u015f V, \u00dcnal S, Ayg\u00fcn K, Temel G\u00d6 et al (2021) Are Platelet-related Parameters Predictive of the Prognosis of Hodgkin\u2019s Lymphoma?","DOI":"10.4274\/BMJ.galenos.2021.35403"},{"key":"5904_CR51","doi-asserted-by":"publisher","first-page":"942122","DOI":"10.3389\/fonc.2022.942122","volume":"12","author":"S Xie","year":"2022","unstructured":"Xie S, Yu Z, Feng A, Zheng S, Li Y, Zeng Y et al (2022) Analysis and prediction of relative survival trends in patients with non-hodgkin lymphoma in the United States using a model-based period analysis method. Front Oncol 12:942122","journal-title":"Front Oncol"},{"issue":"11","key":"5904_CR52","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1182\/bloodadvances.2022009507","volume":"7","author":"MJ Gordon","year":"2023","unstructured":"Gordon MJ, Duan Z, Zhao H, Nastoupil L, Ferrajoli A, Danilov AV et al (2023) A novel comorbidity score for older adults with non-hodgkin lymphoma: the 3-factor risk estimate scale. Blood Adv 7(11):2632\u20132642","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05904-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05904-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05904-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T09:06:06Z","timestamp":1729933566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05904-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["5904"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05904-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"24 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted following the institutional ethics committee and agreement with the Helsinki Declaration of 1975, revised in 2008, and was approved by the Ethical Committee in the Faculty of Medicine, Mansoura University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}